Drug comparisons
Teplizumab vs Pioglitazone
Teplizumab (Tzield) delays T1D via CD3 binding; Pioglitazone (Actos) is a TZD reducing insulin resistance in T2D. Compare immunotherapy vs oral sensitizer.
No comparison dimensions are available for this page.
Clinical context
This comparison may arise when distinguishing disease-modifying therapy for type 1 diabetes from insulin-sensitizing treatment for type 2 diabetes.
Bottom line
Teplizumab and Pioglitazone treat different forms of diabetes and cannot be ranked as better or worse.
All medication comparisons